
Dermatology biotech Krystal settles lawsuit from former partner as it prepares first FDA pitch
Krystal Biotech’s legal troubles with a small partner are over.
The Pittsburgh company settled its trade secrets dispute with PeriphaGen on Tuesday, agreeing to pay $25 million within 10 days of a final agreement and up to four additional payments of $12.5 million each depending on certain product milestones. Krystal admitted no wrongdoing as part of the settlement.
Additionally, all claims against Krystal execs Krish Krishnan and Suma Krishnan were dismissed, as well as counterclaims made against PeriphaGen and its execs, James Wechuck and David Krisky.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.